GKOS Stock Overview
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
My Notes
NewNotes are coming soon
Glaukos Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$48.04 |
52 Week High | US$64.49 |
52 Week Low | US$33.33 |
Beta | 1.2 |
1 Month Change | 9.98% |
3 Month Change | -14.32% |
1 Year Change | -6.88% |
3 Year Change | -14.60% |
5 Year Change | 60.62% |
Change since IPO | 53.88% |
Recent News & Updates
Glaukos sees positive data from mid-stage trial of dry eye treatment
Jan 10Glaukos: Show Me The Money
Nov 10Recent updates
Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?
Oct 16Is Glaukos (NYSE:GKOS) Using Debt Sensibly?
Jun 28Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?
Mar 14Is Glaukos (NYSE:GKOS) Using Debt Sensibly?
Nov 29Is Glaukos (NYSE:GKOS) Weighed On By Its Debt Load?
Aug 15When Should You Buy Glaukos Corporation (NYSE:GKOS)?
Jun 23Here's Why Glaukos Corporation's (NYSE:GKOS) CEO Compensation Is The Least Of Shareholders' Concerns
May 27Is Glaukos (NYSE:GKOS) Weighed On By Its Debt Load?
Apr 30Calculating The Intrinsic Value Of Glaukos Corporation (NYSE:GKOS)
Mar 30At US$89.02, Is It Time To Put Glaukos Corporation (NYSE:GKOS) On Your Watch List?
Mar 04Glaukos' (NYSE:GKOS) Wonderful 524% Share Price Increase Shows How Capitalism Can Build Wealth
Feb 06Shareholder Returns
GKOS | US Medical Equipment | US Market | |
---|---|---|---|
7D | -1.0% | -0.2% | 2.8% |
1Y | -6.9% | -9.7% | -9.2% |
Return vs Industry: GKOS exceeded the US Medical Equipment industry which returned -9.7% over the past year.
Return vs Market: GKOS exceeded the US Market which returned -9.2% over the past year.
Price Volatility
GKOS volatility | |
---|---|
GKOS Average Weekly Movement | 5.7% |
Medical Equipment Industry Average Movement | 8.8% |
Market Average Movement | 6.9% |
10% most volatile stocks in US Market | 17.3% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: GKOS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: GKOS's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 727 | Tom Burns | https://www.glaukos.com |
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company’s product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication.
Glaukos Corporation Fundamentals Summary
GKOS fundamental statistics | |
---|---|
Market Cap | US$2.29b |
Earnings (TTM) | -US$89.61m |
Revenue (TTM) | US$284.88m |
8.0x
P/S Ratio-25.6x
P/E RatioIs GKOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GKOS income statement (TTM) | |
---|---|
Revenue | US$284.88m |
Cost of Revenue | US$68.62m |
Gross Profit | US$216.25m |
Other Expenses | US$305.86m |
Earnings | -US$89.61m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -1.88 |
Gross Margin | 75.91% |
Net Profit Margin | -31.45% |
Debt/Equity Ratio | 51.2% |
How did GKOS perform over the long term?
See historical performance and comparison